secwatch.observer — SEC 8-K summary
======================================

Issuer:     Checkpoint Therapeutics, Inc. (—)
CIK:        0001651407
Form:       8-K
Filed at:   2023-06-13T23:59:59+00:00
Accession:  0001104659-23-070581
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Checkpoint Therapeutics shareholders approve 30M share increase and 3M plan expansion
--------------------------------------------------------------------------------

- Stockholders voted to increase authorized common shares from 50M to 80M (30M increase) on June 12, 2023.
- Amendment to 2015 Incentive Plan approved, increasing shares available from 3M to 6M.
- Seven directors elected with >97% votes for each nominee; KPMG LLP ratified as auditor for FY2023.
- Quorum of 81.98% (25.7M of 31.4M votes) represented at the annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651407/000110465923070581/0001104659-23-070581-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651407/000110465923070581/tm2318470d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-070581

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer